Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction

Do semaglutide and tirzepatide reduce the risk of hospitalization for heart failure or all-cause mortality in patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes in clinical practice?Patients initiating semaglutide or tirzepatide had a more than 40% lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin (a glucose-lowering drug with no effect on heart failure end points). In a head-to-head comparison, tirzepatide showed no meaningful benefit over semaglutide.These findings complement early results from small clinical trials and support the use of semaglutide and tirzepatide in patients with cardiometabolic heart failure with preserved ejection fraction.

Corresponding Author: Nils Krüger, MD, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, 1620 Tremont St, Ste 3030, Boston, MA 02120 (nkruger1@bwh.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.